Pascal Chaux
16Patents
5h-index
29Co-inventors
66Inventor score
Filing activity: Sep 12, 1997 → Oct 15, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5965535A | Mage-3 peptides presented by HLA class II molecules | Chemistry; Metallurgy | 24 | Expired |
| US6291430A | Mage-3 peptides presented by HLA class II molecules | Chemistry; Metallurgy | 20 | Expired |
| US6426217B1 | MAGE-3 peptides presented by HLA class II molecules | Chemistry; Metallurgy | 7 | Expired |
| US6531451B1 | Tumor antigens and CTL clones isolated by a novel procedure | Human Necessities | 7 | Expired |
| US6716809B1 | Mage-A3 peptides presented by HLA class molecules | Chemistry; Metallurgy | 6 | Expired |
| US9504659B2 | Thermoreversible oil-in-water emulsion | Chemistry; Metallurgy | 4 | Active |
| US6710172B1 | Tumor antigens and CTL clones isolated by a novel procedure | Human Necessities | 4 | Expired |
| US7388072B2 | MAGE peptides presented by HLA class II molecules | Human Necessities | 3 | Expired |
| US7049413B2 | MAGE-A3 peptides presented by HLA class II molecules | Human Necessities | 3 | Expired |
| US6369211B1 | MAGE-3 peptides presented by HLA class II molecules | Chemistry; Metallurgy | 2 | Expired |
| US7351409B2 | Tumor antigens and CTL clones isolated by a novel procedure | Human Necessities | 1 | Expired |
| US7157091B1 | MAGE-A1 peptides presented by HLA class II molecules | Emerging Cross-Sectional Technologies | 1 | Expired |
| US11207403B2 | Human cytomegalovirus immunogenic composition | Chemistry; Metallurgy | 0 | Active |
| US7371845B2 | MAGE-A3 peptides presented by HLA class II molecules | Human Necessities | 0 | Active |
| US7252825B2 | MAGE-3 peptides presented by HLA class II molecules | Chemistry; Metallurgy | 0 | Expired |
| US11524069B2 | Human cytomegalovirus immunogenic composition | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.